Anavex Life Sciences Dirección
Dirección controles de criterios 4/4
El CEO de Anavex Life Sciences es Chris Missling , nombrado en Jul 2013, tiene una permanencia de 11.33 años. compensación anual total es $3.89M, compuesta por 18% salario y 82% primas, incluidas acciones y opciones de la empresa. posee directamente un 1.47% de las acciones de la empresa, por valor de $11.39M. La antigüedad media del equipo directivo y de la junta directiva es de 2.8 años y 10.5 años, respectivamente.
Información clave
Chris Missling
Chief Executive Officer (CEO)
US$3.9m
Compensación total
| Porcentaje del salario del CEO | 18.0% |
| Permanencia del CEO | 11.3yrs |
| Participación del CEO | 1.5% |
| Permanencia media de la dirección | 2.8yrs |
| Promedio de permanencia en la Junta Directiva | 10.5yrs |
Actualizaciones recientes de la dirección
Recent updates
Anavex, Cassava Sciences, Panax Ginseng, And The Long-Term Treatment Of Alzheimer's Disease
Nov 11Anavex: Understanding Their Latest Alzheimer's Data News With Caution
Nov 05Anavex Stock: A Risky Bet On CNS Drug Development (Rating Downgrade)
Oct 08Anavex Life Sciences: Short-Lived Spike On Latest Alzheimer's Data Not Surprising
Jul 29Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Jul 17
Here's Why We're Not Too Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Apr 01Here's Why We're Not At All Concerned With Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn Situation
Sep 19We're Interested To See How Anavex Life Sciences (NASDAQ:AVXL) Uses Its Cash Hoard To Grow
May 10Companies Like Anavex Life Sciences (NASDAQ:AVXL) Can Afford To Invest In Growth
Jan 16We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Oct 01Anavex Life Sciences: Upcoming Readouts In Alzheimer's And Parkinson's Disease Dementia
Sep 19Anavex's Blarcamesine And Other Disease Modifying Treatments For Alzheimer's Disease
Sep 07Anavex Life Sciences GAAP EPS of -$0.16 beats by $0.01
Aug 09We Think Anavex Life Sciences (NASDAQ:AVXL) Can Easily Afford To Drive Business Growth
Jun 17Anavex: Increasing Shareholder Value Against All Odds
May 31Anavex's Blarcamesine And Cassava Sciences' Simufilam: The Stabilization Period For Alzheimer's Disease
Mar 23We're Not Worried About Anavex Life Sciences' (NASDAQ:AVXL) Cash Burn
Mar 03Anavex 2-73: A Likely Effective Treatment For Alzheimer's Disease
Feb 09Anavex: Misunderstood Data And Possible Positive FDA Meeting Can Lead To Great Trade Opportunity
Feb 02Anavex: 2022 Has Major, Pivotal Catalysts
Jan 17Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Nov 16Alzheimer's - Cassava, Cortexyme Or Anavex: Who Will Come On Top?
Nov 05Anavex Life Sciences: Still Room To Run
Aug 29Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Jul 30Anavex: A Catalyst-Rich Year
Jul 05Virpax Pharmaceuticals, Anavex Life Sciences leads healthcare gainers; Aptevo Therapeutics, Intec Pharma among major losers
Jun 21Anavex Life outlines mechanism of ANAVEX2-73 and ANAVEX3-71 in treatment of Alzheimer's Disease
Jun 14Anavex Life's late-stage ANAVEX2-73 study in Alzheimer’s exceeds target enrollment
Jun 08Anavex, Cyclo Therapeutics, And Green Valley: Stalling The Progression Of Alzheimer's Disease
Apr 28Anavex Life Sciences (NASDAQ:AVXL) Is In A Strong Position To Grow Its Business
Apr 16Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$42m |
| Mar 31 2024 | n/a | n/a | -US$41m |
| Dec 31 2023 | n/a | n/a | -US$43m |
| Sep 30 2023 | US$4m | US$700k | -US$48m |
| Jun 30 2023 | n/a | n/a | -US$52m |
| Mar 31 2023 | n/a | n/a | -US$53m |
| Dec 31 2022 | n/a | n/a | -US$50m |
| Sep 30 2022 | US$7m | US$586k | -US$48m |
| Jun 30 2022 | n/a | n/a | -US$45m |
| Mar 31 2022 | n/a | n/a | -US$43m |
| Dec 31 2021 | n/a | n/a | -US$41m |
| Sep 30 2021 | US$9m | US$550k | -US$38m |
| Jun 30 2021 | n/a | n/a | -US$32m |
| Mar 31 2021 | n/a | n/a | -US$28m |
| Dec 31 2020 | n/a | n/a | -US$28m |
| Sep 30 2020 | US$2m | US$550k | -US$26m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | n/a | n/a | -US$26m |
| Sep 30 2019 | US$3m | US$513k | -US$26m |
| Jun 30 2019 | n/a | n/a | -US$26m |
| Mar 31 2019 | n/a | n/a | -US$23m |
| Dec 31 2018 | n/a | n/a | -US$20m |
| Sep 30 2018 | US$3m | US$500k | -US$17m |
Compensación vs. Mercado: La compensación total ($USD3.89M) de Chris está en línea con el promedio de empresas de tamaño similar en el mercado US ($USD3.17M).
Compensación vs. Ingresos: La compensación de Chris ha sido consistente con los resultados de la empresa en el último año.
CEO
Chris Missling (58 yo)
11.3yrs
Permanencia
US$3,894,453
Compensación
Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 11.4m | |
| Principal Financial Officer & Treasurer | 9.1yrs | US$501.06k | 0.027% $ 209.2k | |
| Chief Scientific Officer | 2.8yrs | sin datos | sin datos | |
| VP of Corporate | no data | sin datos | sin datos | |
| Senior Vice President of Nonclinical Development | 3.5yrs | sin datos | sin datos | |
| Chief Medical Officer | 2.8yrs | sin datos | sin datos | |
| Head of Biostatistics | 1.7yrs | sin datos | sin datos | |
| Senior Vice President of Regulatory Affairs | less than a year | sin datos | sin datos | |
| Senior Vice President of Clinical Development | less than a year | sin datos | sin datos | |
| Senior VP & Head of Research and Development | less than a year | sin datos | sin datos |
2.8yrs
Permanencia media
Equipo directivo experimentado: El equipo directivo de AVXL se considera experimentado (2.8 años antigüedad media).
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| President | 11.3yrs | US$3.89m | 1.47% $ 11.4m | |
| Independent Chairman | 3.5yrs | US$349.54k | sin datos | |
| Member of the Scientific Advisory Board | 9.7yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 13.8yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 10.9yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 11yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | no data | sin datos | sin datos | |
| Independent Director | 11.8yrs | US$341.54k | 1.54% $ 11.9m | |
| Member of the Scientific Advisory Board | 10.5yrs | sin datos | sin datos | |
| Member of the Scientific Advisory Board | 9.7yrs | sin datos | sin datos | |
| Independent Director | 9.4yrs | US$341.54k | 0.0059% $ 45.6k | |
| Lead Independent Director | 6.7yrs | US$357.54k | sin datos |
10.5yrs
Permanencia media
58yo
Promedio de edad
Junta con experiencia: Los miembros de la junta directiva de AVXL son experimentados ( 10.5 años antigüedad media).